Trexquant Investment LP Acquires 4,921 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Trexquant Investment LP lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 119,584 shares of the biopharmaceutical company’s stock after buying an additional 4,921 shares during the period. Trexquant Investment LP owned approximately 0.09% of Halozyme Therapeutics worth $4,420,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Principal Securities Inc. acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $34,000. First Horizon Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares during the last quarter. Parkside Financial Bank & Trust acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at about $64,000. Headlands Technologies LLC grew its position in Halozyme Therapeutics by 1,068.2% in the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Halozyme Therapeutics by 22.4% during the fourth quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 624 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 40,000 shares of company stock valued at $1,650,600 in the last 90 days. 2.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on HALO. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective on the stock. Benchmark reaffirmed a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. Finally, JMP Securities reduced their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $53.14.

Halozyme Therapeutics Stock Down 0.1 %

Shares of Halozyme Therapeutics stock opened at $45.48 on Thursday. The stock’s 50-day moving average is $40.76 and its 200 day moving average is $38.74. Halozyme Therapeutics, Inc. has a one year low of $31.86 and a one year high of $46.16. The firm has a market cap of $5.79 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 0.51 and a beta of 1.26. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.44 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.